Virax Biolabs (VRAX) Total Current Liabilities (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Total Current Liabilities of $685024.0 for Q1 2026, up 1.76% year-over-year from $673207.0 in Q1 2025, and up 1.76% quarter-over-quarter from $673207.0 in Q1 2025.
Virax Biolabs (VRAX) Total Current Liabilities (2021 - 2026) Analysis & Trends
Virax Biolabs' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $685024.0 for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 1.76% year-over-year to $685024.0; the TTM figure through Mar 2026 stood at $685024.0 (up 1.76% YoY), while the FY2026 annual figure was $685024.0, up 1.76% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $685024.0, up from $673207.0 in the prior quarter.
- The five-year high for Total Current Liabilities was $1.2 million in Q1 2022, with the low at $168849.0 in Q1 2024.
- The 5-year median for Total Current Liabilities is $685024.0 (2026), against an average of $736179.0.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 81.41% in 2024, then surged 298.7% in 2025.
- Virax Biolabs' Total Current Liabilities stood at $1.2 million in 2022, then decreased by 27.06% to $908401.0 in 2023, then slumped by 81.41% to $168849.0 in 2024, then soared by 298.7% to $673207.0 in 2025, then advanced by 1.76% to $685024.0 in 2026.
- Business Quant data shows VRAX's Total Current Liabilities at $685024.0 in Q1 2026, $673207.0 in Q1 2025, and $168849.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | 685,024.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 685,024.00 |
| Mar 31, 2025 | 673,207.00 |
| Mar 31, 2024 | 168,849.00 |
| Mar 31, 2023 | 908,401.00 |
| Mar 31, 2022 | 1.25 Mn |
| Mar 31, 2021 | 871,435.00 |